About Us

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.

Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.

Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.

Actinogen Medical is currently conducting XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in early 2019.

Our Team

Board of Directors

DR. Geoff Brooke

Chairman

READ MORE

Dr. Bill Ketelbey

CEO & Managing Director

READ MORE

DR. Jason Loveridge

Non-Executive Director

READ MORE

Xanamem Clinical Advisory Board

Prof Craig Ritchie (Chair)

READ MORE

Prof Colin Masters AO

READ MORE

Prof Jeffrey Cummings

READ MORE

Scientific Development Panel

Prof Alan Boyd

READ MORE

Prof Brian R Walker

READ MORE

Prof Scott Webster

READ MORE

Actinogen Management

Peter Webse

Company Secretary

READ MORE

Vincent Ruffles

Vice President of Drug Development

READ MORE

Kerrie Boyd

Director of Drug Development

READ MORE

Bridget Rooney

Drug Development Associate

READ MORE

Therese Russell

Executive Assistant and Office Manager

READ MORE

ASX SHARE PRICE

ASX ANNOUNCEMENTS